- Home
- KF vs CRDL Comparison
KF vs CRDL Comparison
Compare KF & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- CRDL
- Stock Information
- Founded
- KF 1984
- CRDL 2017
- Country
- KF United States
- CRDL Canada
- Employees
- KF N/A
- CRDL N/A
- Industry
- KF Investment Managers
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KF Finance
- CRDL Health Care
- Exchange
- KF Nasdaq
- CRDL Nasdaq
- Market Cap
- KF 116.7M
- CRDL 126.5M
- IPO Year
- KF N/A
- CRDL N/A
- Fundamental
- Price
- KF $30.58
- CRDL $1.11
- Analyst Decision
- KF
- CRDL Strong Buy
- Analyst Count
- KF 0
- CRDL 2
- Target Price
- KF N/A
- CRDL $9.00
- AVG Volume (30 Days)
- KF 18.4K
- CRDL 730.6K
- Earning Date
- KF 01-01-0001
- CRDL 11-13-2025
- Dividend Yield
- KF N/A
- CRDL N/A
- EPS Growth
- KF N/A
- CRDL N/A
- EPS
- KF N/A
- CRDL N/A
- Revenue
- KF N/A
- CRDL N/A
- Revenue This Year
- KF N/A
- CRDL N/A
- Revenue Next Year
- KF N/A
- CRDL N/A
- P/E Ratio
- KF N/A
- CRDL N/A
- Revenue Growth
- KF N/A
- CRDL N/A
- 52 Week Low
- KF $18.30
- CRDL $0.77
- 52 Week High
- KF $25.56
- CRDL $2.44
- Technical
- Relative Strength Index (RSI)
- KF 71.98
- CRDL 47.89
- Support Level
- KF $29.45
- CRDL $1.06
- Resistance Level
- KF $30.41
- CRDL $1.10
- Average True Range (ATR)
- KF 0.36
- CRDL 0.06
- MACD
- KF 0.26
- CRDL 0.01
- Stochastic Oscillator
- KF 99.57
- CRDL 52.94
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.